Medicenna Therapeutics (TSE:MDNA) Sets New 12-Month Low - Here's What Happened

Key Points

• Medicenna's stock hit a new 52-week low, trading as low as C$0.60 intraday and last at C$0.64 (up about 4.9% from the prior close) on a volume of 21,093 shares.
• The company has a market cap of C$53.4M, reported C($0.05) EPS for the quarter with analysts forecasting -0.37 EPS for the year, and shows a negative return on equity and an extremely negative net margin.
• Medicenna is a Canada-based immuno-oncology firm developing "Empowered Cytokines" that target the IL-4 receptor, which is overexpressed in ~20 cancers and tumor microenvironment cells.

Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$0.60 and last traded at C$0.64, with a volume of 21093 shares. The stock had previously closed at C$0.61.

Medicenna Therapeutics Stock Up 4.9%

The company has a 50-day simple moving average of C$0.79 and a 200 day simple moving average of C$1.03. The company has a market cap of C$53.39 million, a P/E ratio of -4.27 and a beta of 2.84. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA - Get Free Report) last issued its earnings results on Friday, February 13th. The company reported C($0.05) earnings per share for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, equities analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.